Novel fabrication of Cu(II)-incorporated chiral d-penicillamine-chitosan nanocomposites enantio-selectively inhibit the induced amyloid β aggregation for Alzheimer's disease therapy

Feng Zhao; Hui Yang; Zehong Gao; Huamei Liu; Pingling Wu; Binbin Li; Heming Yu; Jiahui Shao

doi:10.1016/j.heliyon.2023.e23563

Novel fabrication of Cu(II)-incorporated chiral d-penicillamine-chitosan nanocomposites enantio-selectively inhibit the induced amyloid β aggregation for Alzheimer's disease therapy

Heliyon. 2023 Dec 11;10(1):e23563. doi: 10.1016/j.heliyon.2023.e23563. eCollection 2024 Jan 15.

Authors

Feng Zhao¹, Hui Yang², Zehong Gao¹, Huamei Liu², Pingling Wu², Binbin Li², Heming Yu¹, Jiahui Shao³

Affiliations

¹ Department of Neurology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing 210012, China.
² School of Nursing, Nanjing University of Chinese Medicine, Nanjing 210023, China.
³ Department of Neurology, Wenling First People's Hospital Affiliated to Wenzhou Medical University, Wenling 317500, China.

Abstract

It is well known that the chiral materials combined with metal ion's structure have been identified as promising candidate for the nursing Alzheimer Disease (AD) treatment, particularly to inhibit amyloid (Aβ) due to their significant pharmacological effect on the living bodies. In the present study, Cu(II)/Chitosan nanocomposite caped with chiral penicillamine (Cu@D-PEN/Chitosan) have been synthesized and used as an effective amyloid-β (Aβ) inhibitor. The composite formations of the samples were confirmed from the FTIR and XRD, studies. FE-SEM, TEM and AFM studies have been carried out to depict the morphological analysis of the nanocomposites. The prepared samples have also been subjected to various in vitro studies such as encapsulation efficiency, drug loading capacity, drug release and biodegrading or compatibility of the nanocomposites to support the Aβ aggregation inhibiting ability investigations. It was observed that the increase in the concentration of the Cu@D-PEN/Chitosan enhancing the Aβ inhibiting ability. Thus, the Cu(II)@D-PEN/Chitosan showed improving memory effect suggesting that Cu(II)@D-PEN/Chitosan nanocomposites may be a potential candidate for inhibiting the Aβ aggregation in nursing AD treatment.